Market Overview

What's The Thesis On ProQR Now, After Promising Phase 1 Data?

What's The Thesis On ProQR Now, After Promising Phase 1 Data?

ProQR Therapeutics NV (NASDAQ: PRQR), a nano-cap pre-clinical stage bio pharmaceutical company engaged in the discovery and development of ribonucleic acid-based therapeutics for the treatment of severe genetic disorders, announced the completion of a phase 1b study Monday, which helped boost shares of ProQR higher by 4 percent early Tuesday morning.

ProQR's phase 1b safety and tolerability clinical trial of QR-010, a novel investigational RNA therapeutic in subjects with cystic fibrosis, saw favorable tolerability across all doses coupled with no drug related adverse events, Leerink's Joseph Schwartz commented in a research report. Perhaps more important, the company reported improvements in exploratory endpoints, including improvements in patient symptoms according to the CFQ-R (12.5mg dose, p=0.0072) and a 10.9 percent (p=0.0461) improvement in percent predicted forced expiratory volume.

Schwartz maintains an Outperform rating on ProQR's stock with a price target boosted from $10 to $12.

The data report should be viewed as a "positive validation" for the company's RNA repair platform for two reasons, the analyst noted. First, it validates clinical safety and tolerability, and second, it gives the company the opportunity to now evaluate its platform in a bigger and more severe CF population group. However, the company has yet to confirm any future developments but it is evaluation collaborations as a combo therapy or as a monotherapy.

Yet despite the encouraging data, the analyst still sees a 30 percent probability of success which does mark an increase from a prior estimate of just 20 percent. Also, the company's peak penetration now stands at 33 percent which is lower from a prior 45 percent estimate to reflect the "increasingly competitive CF landscape."

At time of publication, shares of ProQR were down 10.76 percent at $5.76.

Related Links:

22 Stocks Moving In Tuesday's Pre-Market Session

The Market In 5 Minutes: Tech Stocks Look To Bounce Back

Latest Ratings for PRQR

Aug 2020Chardan CapitalMaintainsBuy
Nov 2019CitiMaintainsBuy
Nov 2018Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for PRQR
View the Latest Analyst Ratings


Related Articles (PRQR)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Analyst Ratings Movers Trading Ideas General Best of Benzinga

Latest Ratings

MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at